secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001213900-25-010525
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics licenses IL-17A/F antibodies from Paragon; up to $22M in milestones
--------------------------------------------------------------------------------

- Exclusive worldwide license to develop and commercialize Paragon's anti-IL-17A/F antibodies.
- Milestone payments up to $22M, including $1.5M for candidate nomination and $2.5M for first Phase 1 dosing.
- Low single-digit royalty on antibody products; royalty term up to 12 years after first sale.
- Paragon agrees not to conduct new anti-IL-17A/F campaigns in the field for at least 5 years.
- Company may terminate agreement on 60 days' notice; termination for breach or insolvency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390025010525/0001213900-25-010525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390025010525/ea0229970-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-010525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer